| abstract |
The invention relates to aminoquinoline derivatives of the general formula wherein the symbols R¹ to R⁶ hydrogen or one or two of them alkyl and the other hydrogen, R⁷ and R⁸ alkyl, alkenyl, aralkyl or with N together pyrrolidine or piperidine, also substituted by alkyl, octahydroindole or 3-azabicyclo [3,2,2 ] nonane and n = 0 or 1 or wherein the symbols R¹ and R³ tri- or tetramethylene, all other substituents to R⁶ hydrogen, n = 0 and R⁷ and R⁸ have the meanings above or wherein the symbols R¹ and R⁷ methylene or dimethylene and n = 1, R¹ and R⁷ di- or trimethylene and n = 0, R³ and R⁷ di- or trimethylene and n = 1 R³ and R⁷ tri or tetramethylene and n = 0 R⁵ and R⁷ tri or tetramethylene and n = 1 R¹ and R⁵ di- or trimethylene and n = 1, all other substituents are hydrogen, except R⁸, which means alkyl, alkenyl or aralkyl or wherein the symbols R³ and R⁵ tri- or tetramethylene and n = 1, all other substituents up to R⁶ hydrogen and R⁷ and R⁸ alkyl, Alkenyl, aralkyl or pyrrolidine or piperidine together with N, also substituted by alkyl, R⁹ is hydrogen or halogen and R¹⁰ is halogen or trifluoromethyl, and pharmaceutically acceptable salts of basic Compounds of the general formula I for the manufacture of medicaments for combating both chloroquine-resistant and chloroquine-sensitive malaria pathogens. |